We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Durata Wins Approval for Dalvance, First Drug Under New Infectious Disease Designation
Durata Wins Approval for Dalvance, First Drug Under New Infectious Disease Designation
Chicago-based Durata Therapeutics won FDA approval for Dalvance, an antibacterial for skin infections that is the first drug approved under the Qualified Infections Disease Product designation, the agency said Friday.